| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $765.3M+2.6% | $745.9M+8.2% | $689.4M-9.2% | $759.2M-3.2% | $784.6M+25.0% | $627.8M+6.1% | $591.9M+2.4% | $578.2M+3.4% | $559.3M |
| Selling, general and administrative | $743.1M-1.1% | $751.0M+0.4% | $747.9M+12.4% | $665.1M+7.3% | $619.9M+17.2% | $528.9M+2.2% | $517.6M+16.6% | $443.9M+19.6% | $371.3M |
| Amortization of intangible assets | $179.1M+29.3% | $138.5M+0.8% | $137.4M-6.2% | $146.6M+17.4% | $124.9M+11.6% | $111.9M+24.9% | $89.5M+38.1% | $64.8M+56.7% | $41.4M |
| Intangible asset impairment | $211.0M | $0 | $0 | — | — | — | — | — | — |
| Goodwill impairment | $165.0M-23.3% | $215.0M | $0 | $0 | — | — | — | — | — |
| Operating income | $25.2M-88.9% | $227.3M-63.2% | $617.3M-5.2% | $651.0M+10.4% | $589.9M+36.3% | $432.7M+23.2% | $351.2M+6.0% | $331.4M+15.0% | $288.3M |
| Interest income | $4.9M-42.4% | $8.6M+65.0% | $5.2M+566.2% | $780K+19.6% | $652K-21.8% | $834K-45.2% | $1.5M+87.4% | $812K+17.7% | $690K |
| Interest expense | -$107.0M+15.3% | -$126.3M+7.6% | -$136.7M-130.6% | -$59.3M+19.8% | -$73.9M+14.5% | -$86.4M-42.0% | -$60.9M+4.5% | -$63.8M-114.2% | -$29.8M |
| Other income (expense), net | -$22.6M-36.7% | -$16.5M-117.3% | $95.5M+213.0% | $30.5M+185.0% | -$35.9M-135.9% | $100.0M+713.3% | $12.3M-7.3% | $13.3M-64.9% | $37.8M |
| Income (loss) before income taxes | -$99.5M-206.9% | $93.1M-84.0% | $581.3M-6.7% | $623.0M+29.6% | $480.7M | — | — | — | — |
| Provision for income taxes | $42.7M-37.1% | $67.8M-32.8% | $100.9M-22.6% | $130.4M+59.2% | $81.9M+0.1% | $81.8M+63.5% | $50.0M-8.2% | $54.5M-68.2% | $171.4M |
| Net income (loss) | -$142.2M-662.1% | $25.3M-94.7% | $480.4M-2.5% | $492.6M+23.5% | $398.8M+9.2% | $365.3M+43.8% | $254.1M+11.1% | $228.7M+82.3% | $125.4M |
| Less: Net income attributable to noncontrolling interests | $2.2M-29.6% | $3.1M-46.3% | $5.7M-10.0% | $6.4M-18.8% | $7.9M+683.9% | $1.0M-50.9% | $2.0M-13.1% | $2.4M+12.3% | $2.1M |
| Net income (loss) attributable to Charles River Laboratories International, Inc. | -$144.3M-750.1% | $22.2M-95.3% | $474.6M-2.4% | $486.2M+24.4% | $391.0M+7.3% | $364.3M+44.6% | $252.0M+11.3% | $226.4M+83.5% | $123.4M |
| Less: Incremental dividends attributed to noncontrolling interest holders | $0-100.0% | $11.9M | $0 | $0 | — | — | — | — | — |
| Net income (loss) available to Charles River Laboratories International, Inc. common shareholders | -$144.3M-1501.7% | $10.3M-97.8% | $474.6M-2.4% | $486.2M | — | — | — | — | — |
| Basic (in dollars per share) | -$2910.00-1555.0% | $200.00-97.8% | $9270.00-3.1% | $9570.00+23.2% | $7770.00+5.7% | $7350.00+42.2% | $5170.00+9.5% | $4720.00+81.5% | $2600.00 |
| Diluted (in dollars per share) | -$2910.00-1555.0% | $200.00-97.8% | $9220.00-2.7% | $9480.00+24.7% | $7600.00+5.6% | $7200.00+42.0% | $5070.00+9.7% | $4620.00+81.9% | $2540.00 |
| Basic (in shares) | 49.6M-3.5% | 51.4M+0.3% | 51.2M+0.8% | 50.8M+1.0% | 50.3M+1.5% | 49.5M+1.7% | 48.7M+1.6% | 47.9M+1.0% | 47.5M |
| Diluted (in shares) | 49.6M-4.0% | 51.6M+0.3% | 51.5M+0.3% | 51.3M-0.2% | 51.4M+1.6% | 50.6M+1.8% | 49.7M+1.4% | 49.0M+0.9% | 48.6M |
| Service | |||||||||
| Cost of revenue (excluding amortization of intangible assets) | $377.3M+1.3% | $372.4M+12.5% | $330.9M-10.6% | $370.1M-79.9% | $1.84B+19.8% | $1.53B+11.8% | $1.37B+19.2% | $1.15B+32.7% | $867.0M |
| Product | |||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.